ClarusBIOTECH REVIEWAccess & commercial valueHistorical case analysis
Amgen v. Sanofi: antibody breadth needs enabling evidence
The 2023 decision puts a measurable boundary around a broad molecular-platform narrative.
The archive.
Earlier perspectives remain part of the conversation. Explore pieces resting from the homepage, with their original articles and sources intact.
Browse the complete article library
Classic cases and consulting studies
ClarusBIOTECH REVIEWDelivery & enabling technologyHistorical case analysis
qHTS: automate the evidence, then measure the workflow
The NIH titration-screening example shows why a richer experiment can matter more than a throughput ranking.
ClarusBIOTECH REVIEWEvidence & developmentHistorical case analysis
Remdesivir and ACTT-1: five fewer recovery days is a specific claim
A 2020 trial shows why recovery time, mortality, and hospital economics require separate interpretations.